Trial · NCT02339740
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients | Up to 24 months | Patients ineligible, did not start treatment, or RQPCR positive not confirmed are excluded from analyses of EFS | percentage of participants | NUMBER |
| PRIMARY | EFS in High Risk APL Patients | Up to 24 months | Patients ineligible, did not start treatment, or RQPCR positive not confirmed are excluded from analyses of EFS | percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | Induction Death Rate for Patients With FLT3 Mutations and Wild Type FLT3 | Up to 70 days | |||
| OTHER_PRE_SPECIFIED | Disease Free Survival (DFS) | Up to 70 days | |||
| OTHER_PRE_SPECIFIED | Incidence of Serious Early Coagulopathy Events, Defined as Grade 3 or Higher Hemorrhage or Thrombosis | Up to 29 days of induction therapy | |||
| OTHER_PRE_SPECIFIED | Change in CogState Scores, Defined as a Decline of 5 Units in Mean Scores Apparent at 2 Years Off Therapy | End of induction up to 2 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Parent-reported Executive Functioning Over Time, Defined as a Decline of 5 Units in Mean Scores Apparent at 2 Years Off Therapy | End of induction up to 2 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Intellectual Functioning, Defined by Declines on the Wechsler-derived Estimated Intelligence Quotient and Processing Speed Scores | End of treatment to 4 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Memory Functioning, Defined by Declines on the Children's Memory Scale Faces and Stories Memory Scores | End of treatment to 4 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Verbal Learning Functioning, Defined by Declines on the California Verbal Learning Test Total Score | End of treatment to 4 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Adaptive Functioning, Defined by Declines on the Adaptive Behavior Assessment System-II General Adaptive Behavior Composite Score | End of treatment to 4 years post-treatment | |||
| OTHER_PRE_SPECIFIED | Change in Parent-reported Psychosocial Functioning Over Time | End of treatment to 4 years off-therapy | |||
| OTHER_PRE_SPECIFIED | Change in Parent-reported Quality of Life (QOL) Over Time | End of treatment to 4 years |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02339740/outcomes